冠状动脉支架的演变:创新、抗血栓策略与未来方向
本文综述了药物洗脱支架(DES)在平台、聚合物和药物方面的进化,以及经皮冠状动脉介入治疗(PCI)中抗血栓治疗的进展。DES设计趋向薄 strut 和生物相容/可吸收聚合物或无聚合物,超薄 strut DES 在某些研究中表现优于传统 DES。抗血栓治疗方面,可靠 P2Y12 抑制使早期降阶为单药治疗(尤其替格瑞洛)在缺血风险控制良好且支架血栓风险低时合理,但需平衡出血风险。
要点
- DES平台趋向薄 strut 和生物相容/可吸收聚合物或无聚合物,超薄 strut DES 在某些研究中优于传统 DES。
- PCI后默认DAPT疗程:ACS 12个月,CCS 6个月,但早期降阶为单药治疗(尤其替格瑞洛)常合理。
- 抗血栓治疗降低支架血栓及非PCI相关血栓事件,但增加出血风险,需个体化权衡。
核心结论
- DES平台、聚合物和药物的进化提高了 deliverability 和安全性,超薄 strut DES 在某些研究中表现更好。
- 抗血栓治疗进展和风险因素控制降低了血栓风险,但出血风险增加,早期降阶 DAPT 合理。
- 未来 PCI 可能更多采用「leave nothing behind」策略和优化缺血风险因素的药物选项。
研究设计与样本
- 综述文章,未报告系统检索范围或样本量。
主要发现
- DES平台通常为薄 strut with 紧凑的生物相容或生物可吸收聚合物层,或无聚合物。
- 超薄 strut DES 在某些研究中表现优于传统 DES,但在慢性完全闭塞 PCI 等挑战性设置中可能发生 recoil。
- 支架植入进展包括更注重病变准备和支架后优化,增加冠脉内成像使用。
- 抗血栓治疗进步使可靠 P2Y12 抑制成为可能,有助于降低血栓风险。
- 12个月 DAPT(ACS PCI后)和6个月(CCS PCI后)仍是默认推荐策略。
关键数值与推荐
- ACS PCI后默认 DAPT 12个月,CCS PCI后默认 DAPT 6个月。
- 早期降阶为单药治疗(尤其替格瑞洛)在可靠 P2Y12 抑制、缺血风险因素控制良好和支架血栓风险低时合理。
- 较长疗程 DAPT 保留给缺血风险最高但出血风险不高的患者。
临床怎么用
- 根据患者缺血和出血风险个体化 DAPT 疗程,考虑早期降阶为单药治疗。
- 在 PCI 中注重病变准备和支架后优化,使用冠脉内成像识别和解决问题。
- 选择支架时考虑超薄 strut DES 的潜在益处和挑战性设置中的风险。
局限性
- 综述文章,未报告系统检索策略或纳入研究的偏倚评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Implantation of drug-eluting stents (DESs) remains central to percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) and chronic coronary syndromes (CCS). DES platforms, polymers and drugs have evolved significantly to improve deliverability and safety, now being typically thin-strut with a compact layer of biocompatible or bioresorbable polymer, or no polymer at all. Ultra-thin-strut DESs push this concept further, and in some studies perform better than conventional DES, but may recoil in challenging settings such as chronic total occlusion PCI. Stent implantation has also progressed, with greater attention to lesion preparation and poststenting optimisation, increased use of intracoronary imaging helping to recognise and remedy issues. In parallel, antithrombotic therapy for patients undergoing PCI has advanced considerably, with reliable P2Y12 inhibition now possible with the newest agents. As well as progress in controlling other thrombotic risk factors such as hyperlipidaemia, hypertension and diabetes, these developments have contributed to reducing thrombotic risk. As well as preventing stent thrombosis, antithrombotic therapy can reduce the risk of non-PCI-related thrombotic events, not only in the coronary tree but also in the cerebral and peripheral circulation, however it increases bleeding risk. Twelve months of dual antiplatelet therapy (DAPT) after PCI for ACS (and 6 months after PCI for CCS) remains the default recommended strategy, but given reliable P2Y12 inhibition, good control of ischaemic risk factors and a minimally thrombogenic stent design and deployment, it is rational that earlier de-escalation to monotherapy, particularly with ticagrelor, is often appropriate, reserving longer-duration DAPT for those with highest ischaemic risk but where bleeding risk is not high. A body of trial evidence now supports this. As well as earlier de-escalation of DAPT, future developments in PCI might include increased use of 'leave nothing behind' strategies and further pharmacological options for optimisation of ischaemic risk factors.
引用
- Parker. Evolution of coronary stents: innovations, antithrombotic strategies and future directions. Heart. 2025. PMID: 40037763. doi:10.1136/heartjnl-2024-324744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。